Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ 1993; 307: 982–6.PubMedCrossRefGoogle Scholar
Nicholson KG. Human influenza. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Black-well Science, 1998: 219–64.Google Scholar
Piedra PA. Influenza virus pneumonia: pathogenesis, treatment, and prevention. Semin Resp Infect 1995; 10: 216–23.Google Scholar
Centers for Disease Control and Prevention (CDC). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1998; 47 RR-6: 1–29.Google Scholar
Levy E. French economic evaluations of influenza and influenza vaccination. Pharmacoeconomics 1996; 9 (3 Suppl.): 62–6.PubMedCrossRefGoogle Scholar
Monto AS, Sullivan KM. Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect 1993; 110: 145–60.PubMedCrossRefGoogle Scholar
Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza A in healthy working adults. N Engl J Med 1995; 33: 889–93.CrossRefGoogle Scholar
Smith A. The socioeconomic aspects and behavioural effects of influenza. In: Wood C, editor. Influenza: strategies for Prevention. London: Royal Society of Medicine, 1988: 46–52.Google Scholar
Murphy BR, Webster RG. Orthomyxoviruses. In: Fields BN, Knipe DM, Howley PM, editors. Straus Fields’ virology. 3rd ed. Philadelphia (PA): Lippincott-Raven, 1996: 1397–445.Google Scholar
Laver WG, Bischofberger N, Webster RG. Disarming flu viruses. Sci Am 1999; 280 (1): 78–87.PubMedCrossRefGoogle Scholar
Zimmerman RK, Ruben FL, Ahwesh ER. Influenza, influenza vaccine, and amantadine/rimantadine. J Fam Pract 1997; 45: 107–22.PubMedGoogle Scholar
Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 1992; 176: 119–30.PubMedCrossRefGoogle Scholar
Hayden FG, Gwaltney Jr JM, van de Castle RL, et al. Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob Agents Chemother 1981; 19: 226–33.PubMedCrossRefGoogle Scholar
Dolin R, Reichman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982; 307: 580–4.PubMedCrossRefGoogle Scholar
Hay AJ. The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel protein. Semin Virol 1992; 3: 21–30.Google Scholar
Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983; 303: 41–4.PubMedCrossRefGoogle Scholar
Palese P, Tobita K, Ueda M, et al. Characterization of temperature sensitive influenza virus mutants. Virology 1974; 61: 397–410.PubMedCrossRefGoogle Scholar
Palese P, Complans RW Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoro-acetylneuraminic acid (FANA): mechanism of action. J Gen Virol 1976; 33: 159–63.PubMedCrossRefGoogle Scholar
Liu C, Eichelberger MC, Complans RW, et al. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol 1995; 69: 1099–106.PubMedGoogle Scholar
Klenk HD, Rott R. The molecular biology of influenza virus pathogenicity. Adv Virus Res 1988; 34: 247–80.PubMedCrossRefGoogle Scholar
von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363: 418–23.CrossRefGoogle Scholar
Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997; 119: 681–90.PubMedCrossRefGoogle Scholar
Mendel DB, Tai CY, Escarpe PA, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 1998; 42: 640–6.PubMedGoogle Scholar
Hayden FG, Rollins BS. In vitro activity of the neuraminidase inhibitor GS 4071 against influenza viruses [abstract 159]. Antiviral Res 1997; 34: A86.Google Scholar
Hayden FG, Rollins BS, Madren LK. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res 1994; 25: 123–31.PubMedCrossRefGoogle Scholar
Woods JM, Bethell RC, Coates JAV, et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993; 37: 1473–9.PubMedCrossRefGoogle Scholar
Sidwell RW, Huffman JH, Barnard DL, et al. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res 1998; 37: 107–20.PubMedCrossRefGoogle Scholar
Roberts NA, Carr JC, Lambkin R, et al. Oral administration of the neuraminidase inhibitor prodrug GS4104 blocks influenza virus replication in ferrets [abstract]. European Respiratory Society Annual Congress; 1998 Sep 19–23; Geneva.
Oxford JS, Roberts N, Kelly L, et al. Targeting influenza infection through neuraminidase inhibition: GS4104 activity in the ferret model [abstract]. European Society for Clinical Virology — Progress in Virology VI; 1998 Aug 30–Sept 2; Hamburg
Sidwell RW, Burger RA, Huffman JH, et al. Immunological effects of the orally administered neuraminidase inhibitor GS4104 in influenza virus-infected and uninfected mice [abstract]. 38th Interscience Conference of Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego.
F. Hoffmann-La Roche Ltd, Gilead Sciences. Investigational drug brochure, oseltamivir [GS4104/Ro 640796/neuraminidase inhibitor]. F. Hoffmann-La Roche Ltd and Gilead Sciences, 1997.
Cundy KC, Eisenberg G, Bidgood A, et al. The novel influenza neuraminidase inhibitor prodrug GS4104 is highly bioavailable in animals [abstract H123]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 237.
Li W, Escarpe PA, Eisenberg EJ, et al. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998; 42 (3): 647–53.PubMedGoogle Scholar
Wiltshire HR, Muir J, Lambkin R, et al. Distribution pattern of GS4071, a novel influenza neuraminidase inhibitor, following oral administration of its prodrug GS4104 in the ferret model [abstract and poster]. European Society for Clinical Virology; 1998 Aug 30–Sep 2; Hamburg.
Cundy KC, Eisenberg G, Bidgood A, et al. Enhanced delivery of the novel influenza neuraminidase inhibitor GS4071 to rat lung after oral administration of the prodrug GS4104 [abstract A-122]. 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 25.
Eisenberg EJ, Bidgood A, Cundy KC. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrob Agents Chemother 1997; 41: 1949–52.PubMedGoogle Scholar
Wiltshire HR, Wiltshire BG. An integrated summary of the analytical methods used and data obtained during the clinical and pre-clinical development of Ro 64-0796/002. Research report W-143081, 1999. (Data on file).
He G, Massarella J, Schulz R, et al. The absolute bioavailability of the novel oral neuraminidase inhibitor Ro 64-079/GS4104 [abstract]. American Association of Pharmaceutical Scientists, Southeast Regional Meeting; 1999 Jun 21; Durham, NC.
He G, Massarella J, Schulz R, et al. The effect of food on the pharmacokinetics of the novel oral neuraminidase inhibitor Ro 64-0796/GS4104 [abstract]. American Association of Pharmaceutical Scientists, Southeast Regional Meeting; 1999 Jun 21; Durham, NC.
Wiltshire HR. A cross-species comparison of the protein-binding and red cell partitioning of Ro 64-0796 and Ro 64-0802 (DHB08201 and DHB0802). Research report W-143012, 1998. (Data on file).
Wiltshire HR. An investigation of the potential inhibitory effect of Ro 64-0796 and Ro 64-0802 on the metabolism of cytochrome P450 model substrates. Research report W-142919, 1998. (Data on file).
Wood ND, Aitken M, Sharp S, et al. Tolerability and pharmacokinetics of the neuraminidase inhibitor Ro 64-0802 (GS4071) following oral administration of the prodrug Ro 64-0796 (GS4104) to healthy male volunteers [abstract A-123]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 25.
Algranati NE, Massarella JW, Wood ND, et al. Pharmacokinetics and tolerability of the influenza neuraminidase inhibitor Ro 64-0802 following multiple dose oral administration of the prodrug Ro 64-0796 to healthy young and elderly subjects [abstract and poster]. European Respiratory Society Annual Congress; 1998 Sep 19–23; Geneva.
He G, Massarella J, Robson R, et al. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor Ro 64-0796/GS4104 in subjects with renal impairment [abstract and poster]. 9th European Congress of Clinical Microbiology and Infectious Diseases; 1999 Mar 21–24; Berlin.
Grosse M. Clinical study report — protocol NP15717. Study of the PD and PK of the neuraminidase inhibitor Ro 64-0796 (GS4104) in the treatment of volunteers experimentally infected with human influenza B virus. Research report W-144105, 1999. (Data on file).
Dorkings J. Clinical study report — protocols WV 15670, WV 15671 and WV 15730. Areport on the pharmacokinetic results from the phase III studies for the neuraminidase inhibitor Ro 64-0796. Research report W-144130, 1999. (Data on file).
He G, Massarella J, Aitken M, et al. The safety and pharmacokinetics of the neuraminidase inhibitor Ro 64-0796 when administered concurrently with paracetamol [abstract]. 9th European Congress of Clinical Microbiology and Infectious Diseases; 1999 Mar 21–24; Berlin.
He G, Massarella J, Aitken M, et al. The pharmacokinetics and safety of the oral neuraminidase inhibitor R0 64-0796/GS4104 when administered concurrently with cimetidine or probenecid in healthy subjects [abstract]. 21st International Congress of Chemotherapy; 1999 Jul 4–7; Birmingham.
Small I, Oo C, Dorr A, et al. Clinical study report — protocol NP15901. An open-label, two-way crossover, randomised pharmacokinetic drug interaction study of neuraminidase inhibitor Ro 64-0796/GS4104 and amoxicillin in healthy volunteers. Research report W-144169, 1999. (Data on file).
He G, Massarella J, Schulz R, et al. The relative bioavailability of early clinical and market formulations of the novel oral neuraminidase inhibitor Ro 64-0796/GS4104. 2nd European Congress of Pharmacology; 1999 Jul 3–7; Budapest.